WEIGHT LOSS · Injectable
Adipotide.
Adipose-targeting fat loss peptide
How it works
Class & mechanism.
Class
Proapoptotic Vascular-Targeting Peptidomimetic
Mechanism
Adipotide (FTPP / CKGGRAKDC-GG-D(KLAKLAK)2) is a chimeric peptidomimetic consisting of two functional domains linked by a Gly-Gly bridge. The homing domain (CKGGRAKDC) selectively binds the prohibitin–annexin A2 receptor complex expressed exclusively on the endothelial cells of white adipose tissue vasculature — a discovery enabled by vascular ZIP code mapping at MD Anderson Cancer Center. Upon receptor-mediated internalization, the proapoptotic domain D(KLAKLAK)2 disrupts mitochondrial membranes in those targeted endothelial cells, triggering apoptosis and collapsing the vascular supply to white fat depots. Fat cells deprived of their blood supply are subsequently metabolized and reabsorbed, while the disrupted adipose vasculature also independently signals reduced food intake through a leptin-independent hypothalamic pathway.
Did you know
Adipotide works on a principle never used in any approved drug: it physically destroys the blood vessels that feed fat cells — without touching any other vessels in the body. This 'vascular ZIP code' discovery showed that the blood vessels supplying white fat carry a unique molecular address (prohibitin receptor), making fat the first tissue that can be precisely 'starved' of its blood supply as a therapeutic strategy.
Benefits
What it does.
Directly targets and eliminates white adipose tissue vasculature without affecting brown fat or other organs
~30% body weight reduction in obese rodents over 28 days; ~11% reduction and 39% decrease in fat deposits in obese non-human primates
Improved insulin resistance — obese monkeys required ~50% less insulin after treatment
Reduction in food intake via a novel leptin-independent mechanism signaling from the altered adipose vasculature
Selective action on visceral and subcutaneous white fat with preservation of brown adipose tissue
Potential oncological applications via prohibitin targeting — opens pathway for tumor vasculature research
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
Barnhart et al. (2011): Adipotide induced ~11% body weight loss and ~39% fat deposit reduction in spontaneously obese rhesus macaques over 28 days, with concurrent improvements in insulin resistance — obese monkeys required ~50% less insulin post-treatment
SOURCE · Science Translational Medicine, Barnhart et al., 2011 (PMC3666164)
Kolonin et al. (2004): Targeted apoptosis of white adipose tissue vasculature via CKGGRAKDC-prohibitin binding caused ~30% body weight reduction in obese mice over 4 weeks, with normalization of metabolic processes and no significant off-target effects
SOURCE · Science, Kolonin et al., 2004
Diabetes (2010): Proapoptotic adipose vasculature peptide reduced food intake in obese rodents without changes in energy expenditure and despite falling leptin levels, revealing a novel adipose-to-hypothalamus signaling pathway
SOURCE · Diabetes, Seeley et al., 2010 (PMC2844838)
Primate GLP safety study: Three dose levels (0.25, 0.43, 0.75 mg/kg daily × 28 days) showed dose-dependent, predictable, and reversible renal tubular effects — classified as minimal to moderate kidney lesions — with no irreversible organ damage
SOURCE · GLP Primate Safety Study, Arrowhead Pharmaceuticals
Protocol
How to use it.
Dosing
Research use only. Preclinical primate efficacy protocol: daily subcutaneous injection for 28 consecutive days. Doses in primate models ranged from 0.25–0.75 mg/kg/day; efficacy balanced against renal effects at intermediate doses. No validated human dosing protocol established. All published studies used a 28-day treatment cycle followed by discontinuation.
Cycle
28-day cycles based on all published preclinical data. No published data on repeated cycles or chronic use — renal toxicity mechanism (D-amino acid oxidase metabolism in renal tubules) makes extended continuous use problematic. Clinical translation was planned for obese prostate cancer patients (28-day cycle), but no completed human trials have been published.
Contraindications
When to skip it.
Pre-clinical stage only — no approved human use. Primary safety concern is dose-dependent renal toxicity: elevated serum creatinine, tubular degeneration, single-cell necrosis, and altered tubular function observed in all primate studies. Effects were classified as reversible and predictable. Dehydration compounds kidney risk. Not suitable for patients with pre-existing renal impairment. Does not affect brown adipose tissue, lean mass, or organ vasculature at studied doses.
Always cleared with your concierge before protocol start.
Pricing
What it costs.
Indicative range for Adipotide, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Includes vial and reconstitution guidance
- 03Concierge supplier match included with every protocol
See Adipotide pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $124–$186 USD